```html

Zollinger‑Ellison Syndrome (Gastrinoma) – A Patient‑Friendly Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing tumors—called gastrinomas—develop in the pancreas, duodenum, or nearby tissues. These tumors secrete excess gastrin, a hormone that stimulates the stomach lining to make large amounts of gastric acid. The resulting hyperacidity leads to severe peptic ulcers, diarrhea, and a host of other gastrointestinal problems.

• Who it affects: Most patients are adults aged 30‑60, but ZES can occur at any age, including in children.
• Prevalence: Approximately 0.1–0.3 cases per 100,000 people worldwide. About 20‑25 % of gastrinomas are associated with a genetic condition called Multiple Endocrine Neoplasia type 1 (MEN‑1) <sup>[1][2]</sup>.
• Gender: Slight male predominance (≈55 % male).

Symptoms

Symptoms arise from the excess acid and from the tumor itself. They can vary widely, making diagnosis challenging.

Gastro‑intestinal manifestations

• Refractory duodenal or gastric ulcers: Ulcers that do not heal with standard proton‑pump inhibitor (PPI) therapy and may recur in unusual locations (e.g., jejunum).
• Abdominal pain: Burning or gnawing pain often worsened by meals.
• Diarrhea: Occurs in up to 70 % of patients; can be watery, fatty (steatorrhea), or both due to acid‑induced malabsorption.
• Nausea & vomiting: May be triggered by ulcer bleed or obstruction.
• Gastro‑esophageal reflux disease (GERD): Persistent heartburn from high acid load.

Systemic manifestations

• Weight loss: Result of chronic diarrhea, malabsorption, and reduced appetite.
• Fatigue & anemia: From chronic blood loss or iron deficiency.
• Skin changes: Occasionally, pigmentary changes or flushing (more common in MEN‑1).

Signs related to tumor presence

• Palpable abdominal mass: Rare, usually when tumors are large.
• Metastatic symptoms: If the tumor spreads to the liver or lymph nodes, patients may develop right‑upper‑quadrant pain or jaundice.

Causes and Risk Factors

Zollinger‑Ellison syndrome is primarily caused by gastrin‑producing neuroendocrine tumors. The underlying mechanisms differ between sporadic cases and those linked to genetic syndromes.

Primary causes

• Sporadic gastrinomas: Approximately 75 % of ZES cases arise without an inherited disorder. Most of these tumors are located in the duodenum (≈55 %) or pancreas (≈30 %).
• Multiple Endocrine Neoplasia type 1 (MEN‑1): An autosomal‑dominant mutation in the MEN1 tumor suppressor gene. Patients develop multiple endocrine tumors, including gastrinomas, parathyroid adenomas, and pituitary adenomas. Up to 25 % of ZES patients have MEN‑1 <sup>[2]</sup>.

Risk factors

• Family history of MEN‑1 or other endocrine neoplasias.
• Known MEN1 gene mutation.
• Prior history of pancreatic or duodenal neuroendocrine tumors.
• Age 30‑60 (peak incidence).
• Male sex (slight increase).

Diagnosis

Because symptoms overlap with common peptic‑ulcer disease, a structured diagnostic approach is essential.

Laboratory tests

• Fasting serum gastrin level: A level > 1,000 pg/mL (≈10 × upper limit) is highly suggestive of ZES, especially when gastric pH < 2. <sup>[3]</sup>
• Secretin stimulation test: In ZES, gastrin paradoxically rises > 120 pg/mL after IV secretin; this test helps differentiate ZES from other causes of hypergastrinemia.
• Endoscopic evaluation: Upper endoscopy (EGD) visualizes ulcers and can obtain biopsies to rule out malignancy.

Imaging studies

1. Multiphasic contrast‑enhanced CT or MRI: Detects primary tumor and metastases; sensitivity ≈70‑80 % for lesions > 1 cm.
2. Somatostatin receptor scintigraphy (Octreoscan) or ^68Ga‑DOTATATE PET/CT: Gold standard for locating small neuroendocrine tumors; sensitivity > 90 % for gastrinomas < 1 cm.
3. Endoscopic ultrasound (EUS): Provides high‑resolution images of pancreatic head and duodenal wall; useful for fine‑needle aspiration (FNA) biopsy.

Histopathology

When tissue is obtained, pathologists look for neuroendocrine markers (chromogranin A, synaptophysin) and Ki‑67 index to grade tumor aggressiveness.

Treatment Options

Management aims to control acid hypersecretion, remove or control tumor growth, and monitor for recurrence.

Medical therapy – controlling acid

• High‑dose Proton Pump Inhibitors (PPIs): Omeprazole 60‑80 mg/day or equivalent; most patients achieve symptom control. PPIs are the first‑line, lifelong therapy for acid suppression <sup>[4]</sup>.
• Histamine‑2 receptor antagonists (H2 blockers): Used adjunctively if PPIs insufficient.
• Somatostatin analogues (Octreotide, Lanreotide): Reduce gastrin secretion and may shrink tumor size; especially useful in MEN‑1 or metastatic disease.

Surgical options

• Curative resection: Preferred for solitary, localized gastrinomas (e.g., duodenal <1 cm). Pancreaticoduodenectomy (Whipple) may be required for larger pancreatic tumors.
• Enucleation: Removal of small, well‑encapsulated tumors while preserving pancreatic tissue.
• Debulking surgery: For metastatic disease to reduce tumor burden and improve symptom control.

Targeted and systemic therapies

• Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; shown to improve progression‑free survival.
• Chemotherapy: Typically reserved for high‑grade (Ki‑67 > 20 %) neuroendocrine carcinomas; regimens include streptozocin + 5‑FU or temozolomide‑capecitabine.
• mTOR inhibitor (Everolimus) or multikinase inhibitor (Sunitinib): FDA‑approved for advanced pancreatic neuroendocrine tumors; may be considered when disease is progressive.

Lifestyle and supportive care

• Small, frequent meals to lessen acid load.
• Avoidance of alcohol, caffeine, nicotine, and NSAIDs, which aggravate ulcer disease.
• Maintain adequate hydration and replace electrolytes lost through diarrhea.

Living with Zollinger‑Ellison Syndrome (gastrinoma)

Long‑term management focuses on symptom control, monitoring, and quality of life.

Medication adherence

• Take PPIs exactly as prescribed; do not discontinue abruptly.
• Keep a medication diary; note any breakthrough symptoms that may require dose adjustment.

Nutrition

• Eat low‑fat, low‑spice meals; high‑protein foods are generally well tolerated.
• Consider a dietitian referral for individualized meal planning, especially if malabsorption is present.
• Supplement with calcium, vitamin D, and iron if deficiencies develop.

Follow‑up schedule

• Every 3‑6 months: Clinical review, fasting gastrin level, and PPI dose check.
• Annually: Imaging (CT/MRI or DOTATATE PET) to assess for tumor recurrence or metastasis.
• For MEN‑1 patients, coordinate with endocrinology for surveillance of other endocrine organs.

Psychosocial support

Living with a chronic rare disease can be stressful. Join support groups (e.g., Neuroendocrine Tumor Research Foundation) and consider counseling if anxiety or depression arise.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for individuals with a family history of MEN‑1.
• Early screening (annual fasting gastrin measurement and imaging) for known MEN‑1 carriers.
• Avoid chronic use of proton‑pump inhibitors for unrelated conditions without clear indication—over‑suppression may mask early symptoms.

Complications

If untreated or inadequately controlled, ZES can lead to serious health problems.

• Peptic ulcer perforation: Can cause peritonitis, requiring emergency surgery.
• Massive GI bleeding: From ulcer erosion into vessels.
• Gastro‑intestinal obstruction: Due to scarring or tumor bulk.
• Malabsorption & nutritional deficiencies: Chronic diarrhea leads to loss of fats, vitamins (A, D, E, K), and electrolytes.
• Metastatic disease: ~50 % of gastrinomas metastasize to liver or regional lymph nodes; prognosis depends on tumor grade and burden.
• Secondary osteoporosis: Chronic acid excess and malabsorption can impair calcium/vitamin D absorption.

When to Seek Emergency Care

References

1. F. V. Saftig & R. A. Jensen. Neuroendocrine Tumors of the Pancreas and Duodenum. Nature Reviews Endocrinology, 2021.
2. American Association of Endocrine Surgeons. Guidelines for Management of MEN‑1. 2023.
3. Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2024. https://www.mayoclinic.org
4. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Treatment for Zollinger‑Ellison syndrome.” 2022.
5. World Health Organization. “Neuroendocrine tumours: WHO classification.” 2024.

```